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Abstract
Background.—Data are limited on the impact of neuraminidase inhibitor (NAI) treatment on 
avian influenza A(H7N9) virus RNA shedding.
Methods.—In this multicenter, retrospective study, data were collected from adults hospitalized 
with A(H7N9) infection during 2013–2017 in China. We compared clinical features and A(H7N9) 
shedding among patients with different NAI doses and combination therapies and evaluated factors 
associated with A(H7N9) shedding, using Cox proportional hazards regression.
Results.—Among 478 patients, the median age was 56 years, 71% were male, and 37% died. 
The median time from illness onset to NAI treatment initiation was 8 days (interquartile range 
[IQR], 6–10 days), and the median duration of A(H7N9) RNA detection from onset was 15.5 days 
(IQR, 12–20 days). A(H7N9) RNA shedding was shorter in survivors than in patients who died (P 
< .001). Corticosteroid administration (hazard ratio [HR], 0.62 [95% confidence interval {CI}, .
50-.77]) and delayed NAI treatment (HR, 0.90 [95% CI, .91-.96]) were independent risk factors 
for prolonged A(H7N9) shedding. There was no significant difference in A(H7N9) shedding 
duration between NAI combination treatment and monotherapy (P = .65) or between standard-
dose and double-dose oseltamivir treatment (P = .70).
Conclusions.—Corticosteroid therapy and delayed NAI treatment were associated with 
prolonged A(H7N9) RNA shedding. NAI combination therapy and double-dose oseltamivir 
treatment were not associated with a reduced A(H7N9) shedding duration as compared to 
standard-dose oseltamivir.
Keywords
Viral shedding; avian influenza A(H7N9); human; antiviral drug; neuraminidase inhibitors; 
oseltamivir; corticosteroid; risk factor
Since the first 3 patients known to have avian influenza A(H7N9) virus infection were 
reported in March 2013 [1], there have been 5 epidemics of A(H7N9) infections among 
humans to date in mainland China [2]. In these 5 epidemics, most A(H7N9)-infected 
patients were hospitalized with severe illness, with a high resultant mortality rate 
(approximately 40%) [2]. During the fifth epidemic, a sudden increase in the number of 
human cases and the emergence of highly pathogenic A(H7N9) infections raised public 
health concerns [3–7].
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Factors contributing to the pathogenesis of influenza virus infection include direct injury 
caused by infection and viral replication in respiratory epithelial cells and immunopathology 
induced by cytokine dysregulation [8, 9]. Observational studies have reported that prolonged 
influenza viral shedding in the respiratory tract is associated with severe outcomes of 
patients with seasonal influenza [10] and that early initiation of antiviral treatment with 
neuraminidase inhibitors (NAIs) for patients infected with 2009 pandemic influenza 
A(H1N1) virus (A[H1N1] pdm09) has a survival benefit [11–17]. The viral shedding 
duration among patients with seasonal or pandemic influenza has been reported to be 
associated with corticosteroid administration, delayed NAI treatment, and comorbidities [10, 
18].
NAI treatment of A(H7N9)-infected patients in China has included standard-or double-dose 
oseltamivir monotherapy, as well as combination NAI treatment with oseltamivir and 
peramivir. Corticosteroids have also been administered to most A(H7N9)-infected patients. 
Recently, a single institution study reported that A(H7N9) viral shedding duration was 
shorter and that mortality was lower with early initiation of NAI treatment [19]. However, 
the study did not assess the impact of different NAI drug doses, combination NAI treatment, 
or corticosteroid therapy on the duration of A(H7N9) shedding.
We conducted a retrospective, multicenter study of 478 hospitalized patients with 
laboratory-confirmed A(H7N9) infection who were identified during April 2013-March 
2017 to assess the impact of different NAI treatment strategies and corticosteroid treatment 
on the duration of A(H7N9) shedding.
METHODS
Data Collection
Data collection and analysis were coordinated by the Chinese National Health and Family 
Planning Commission. The subjects included in the study were patients with laboratory-
confirmed A(H7N9) infection diagnosed from 1 April 2013 to 1 March 2017. The study 
subjects were expanded from the cohort of 288 hospitalized A(H7N9)-infected patients with 
pneumonia during April 2013-March 2015 that was previously analyzed to assess the impact 
of corticosteroids upon mortality and A(H7N9) shedding [20]. The electronic medical 
records of patients were sent to a data collection center in Beijing, China. Demographic data, 
comorbidities, vital signs, laboratory findings at admission, virological test results, and 
treatments were reviewed by a trained team of physicians and medical students and entered 
in duplicate into a computerized database. As noted previously, the collection of data from 
A(H7N9)-infected patients was determined to comprise public health surveillance in China, 
and institutional review board assessment was waived [20, 21].
Virologie Investigations
A(H7N9) infection was confirmed in all patients by testing respiratory specimens with a 
real-time reverse transcription-polymerase chain reaction (RT-PCR) assay at the local 
laboratory of the Chinese Center for Disease Control and Prevention. Respiratory specimens 
(nasopharyngeal swab specimens, sputum specimens, endotracheal aspirates, or broncho 
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alveolar lavage fluid) were collected daily for detection of A(H7N9) RNA by real-time RT-
PCR. Details of laboratory confirmation of A(H7N9) were described previously [21]. 
Respiratory specimens with cycle threshold (Ct) values of ≤38 were considered positive for 
A(H7N9), and those with Ct values of >38.0 underwent repeat testing. Upon repeated 
testing, respiratory specimens with Ct values of ≤38 were considered positive for A(H7N9), 
and those with Ct values of >38 or with undetectable results were considered negative for 
A(H7N9). We defined the interval between symptom onset and the date of the last A(H7N9) 
RNA-positive result for respiratory samples as the A(H7N9) RNA shedding duration. 
Corticosteroid treatment was defined as administration of a dose equivalent to ≥25 mg of 
methylprednisolone per day during hospitalization [22].
Statistical Analysis
Mean values and standard deviations or median values with interquartile range were used to 
describe continuous variables, and absolute or relative frequencies were used to describe 
categorical variables. We used the Student t test and the MannWhitney U test for analysis of 
continuous variables and the χ2 test or Fisher exact test for analysis of discrete variables in 
bivariate analyses. To identify risk factors associated with prolonged duration of A(H7N9) 
RNA shedding, we performed a time-dependent Cox proportional hazards model that 
adjusted for baseline covariates. Outcomes were defined as times to A(H7N9) RNA 
negativity. For this analysis, we censored patients if they never cleared A(H7N9) RNA or, if 
they were discharged alive before they had cleared A(H7N9) RNA, at hospital discharge. 
Analysis was performed using a marginal structural Cox proportional hazard model [23]. 
Candidate variables considered for analysis of prolonged duration of A(H7N9) shedding 
were sex, age, comorbidities, smoking, time from illness onset to starting antiviral treatment, 
and specific antiviral NAI. We used Kaplan-Meier survival analysis to estimate the 
cumulative A(H7N9) RNA-negativity rate and the stratified log-rank statistic to compare the 
difference of A(H7N9) clearance between different 2 groups (ie, patients who survivors vs 
those who died, patients who started NAI treatment <5 days from illness onset vs those who 
started NAI treatment ≥5 days from illness onset, patients who received oseltamivir vs those 
who received a combination of oseltamivir plus peramivir, and patients who received 
standard-dose oseltamivir vs those who received double-dose oseltamivir). Statistical 
analyses were performed using SPSS, version 20.0 for Windows (IBM, Armonk, NY), and 
SAS, version 9.4 (SAS Institute, Cary, NC). For all analyses, probabilities were 2-tailed, and 
a 2-tailed P value of <.05 was considered significant.
RESULTS
From 1 April 2013 to 1 March 2017, 478 A(H7N9) case patients with virological results 
were included in this study from 16 provinces and 3 municipalities in mainland China. A 
total of 88 patients (18.4%) who tested positive for A(H7N9) RNA until death, and 390 
(81.6%) had resolution of A(H7N9) shedding (Figure 1). The main characteristics and 
outcomes of all patients are summarized in Table 1.
The source of respiratory specimens was available in medical records for 244 patients (51%) 
for detection of the first negative A(H7N9) RNA result. Of the specimens tested that yielded 
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the first negative A(H7N9) RNA test result, 145 (59%) were from an endotracheal aspirate, 
35 (14.3%) were from a sputum specimen, and 64 (26.2%) were from a nasopharyngeal 
swab specimen.
Prolonged Duration of A(H7N9) RNA Shedding
The median duration of A(H7N9) RNA shedding was 15.5 days (interquartile range [IQR], 
12–20 days). Only 7 patients (1.8%) with real-time RT-PCR confirmed A(H7N9) infection 
had undetectable A(H7N9) RNA within 6 days, 42 (10.7%) tested negative within 10 days, 
and 286 (73.1%) tested negative within 20 days of illness onset. A(H7N9) RNA was 
undetectable among most patients (92.3%) within 27 days after symptom onset, but it was 
detectable in a small subset of 22 patients up to 30 days after symptom onset (Figure 2 and 
Supplementary Table 1).
The median duration of A(H7N9) shedding detected in endotracheal aspirate specimens was 
17 days (IQR, 13–21 days) and was similar to the median duration of A(H7N9) shedding 
detected in nasopharyngeal swabs (17 days [IQR, 13–20 days]; hazard ratio [HR], 1.18 
[95% confidence interval {CI}, .78–1.79; P = .43; Supplementary Figure 1). Viral RNA 
clearance was significantly faster in survivors compared with fatal cases (HR, 1.79 [95% CI, 
1.45–2.20]; P < .001; Figure 3A).
Risk Factors for Prolonged Viral Shedding
In a multivariable model that included available data from 478 patients, the time from illness 
onset to antiviral treatment (HR, 0.90 [95% CI, .91-.96]) and systemic corticosteroid 
administration (HR, 0.62 [95% CI, .50-.77]) were independent factors associated with the 
duration of A(H7N9) RNA shedding (Table 2 and Figure 4). Similar risk factors for delayed 
A(H7N9) RNA clearance were observed when the data were analyzed using a marginal 
structural Cox proportional hazards model (Supplementary Table 2).
The median time from illness onset to NAI treatment initiation was 8 days (IQR, 6–10 days). 
A(H7N9) RNA clearance was significantly delayed in patients who received NAI treatment 
beginning ≥5 days after illness onset, compared with those in whom NAI treatment was 
started <5 days after illness onset (HR, 2.64 [95% CI, 1.74–4.03]; P < .001; Figure 3B).
Impact of Different Antiviral Treatment Regimens and Oseltamivir Dosing on Outcomes
Among the 478 patients, antiviral treatment administered included oseltamivir monotherapy 
in 307 (64.2%); peramivir and oseltamivir in 142 (29.7%); peramivir, zanamivir, and 
oseltamivir in 25 (5.2%); oseltamivir and ribavirin in 3 (0.6%); and oseltamivir and 
ganciclovir in 1 (0.2%). The median duration of A(H7N9) shedding was 17 days (range, 13–
21 days) in the oseltamivir monotherapy group and 19 days (range, 14–22 days) in the 
oseltamivir-peramivir combination treatment group. The main characteristics of patients 
who received different antiviral drugs are summarized in Table 3. The median time from 
antiviral treatment initiation to a negative real-time RT-PCR result in respiratory tract 
specimens was 8 days (range, 5–10 days) in the oseltamivir monotherapy group, and 8 days 
(range, 6–9 days) in the oseltamivir-peramivir combination therapy group (P = .76). There 
was no significant difference in duration of A(H7N9) RNA shedding between patients who 
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received oseltamivir monotherapy, compared with those who received oseltami-vir-peramivir 
combination therapy (Figure 3C).
Oseltamivir dosing data were available for 180 patients. There was no difference in 
A(H7N9) RNA clearance (HR, 1.08 [95% CI, .67–1.68]; P = .7; Figure 3D) or in-hospital 
mortality (51.4% and 57.5%, respectively; P = .58; Table 3) between patients who received 
oseltamivir 150-mg twice-daily treatment and those who received 75-mg twice-daily 
treatment.
We further compared the proportion of patients who tested positive for A(H7N9) RNA over 
time after starting NAI treatment, using the log-rank test. There was no significant difference 
among patients who received standard-dose oseltamivir, double-dose oseltamivir, or 
oseltamivir and peramivir treatment (HR, 1.18 [95% CI, .78–1.79]; P = .43; Supplementary 
Figure 2).
DISCUSSION
We report on the largest cohort of hospitalized patients with A(H7N9) infection in China to 
date. This study expands on our prior study of 288 hospitalized A(H7N9)-infected patients 
with pneumonia that reported associations between high-dose corticosteroid therapy and 
increased 30-day and 60-day mortality and a longer duration of A(H7N9) RNA detection 
[20]. In the current study of 478 hospitalized A(H7N9)-infected patients, we identified 
independent risk factors for prolonged A(H7N9) RNA detection and examined the impact of 
different antiviral treatment regimens on A(H7N9) RNA shedding. In most patients, NAI 
treatment was started >48 hours after illness onset, but initiation of NAI treatment before the 
fifth day of ill-ness was associated with a shorter duration of A(H7N9) RNA shedding. 
Combination antiviral treatment with different NAIs and double-dose oseltamivir was not 
associated with significant differences in A(H7N9) RNA shedding or in-hospital mortality, 
compared with standard-dose oseltamivir monotherapy.
We detected A(H7N9) RNA in the respiratory tract for a median of 15.5 days, and prolonged 
A(H7N9) RNA shedding was associated with a fatal outcome. Data on the duration of highly 
pathogenic avian influenza A(H5N1) virus shedding are limited but indicate that A(H5N1) 
RNA can be detected longer and at higher levels in lower respiratory tract tissues, including 
up to 15–27 days in fatal cases, than in upper respiratory tract specimens [24, 25]. A 
systematic review reported that progressively longer shedding duration of A(H1N1)pdm09 
in patients was correlated with disease severity when studies were stratified into community 
(range of mean and median values, 2–9 days), hospital (range of mean and median values, 
6–10 days), and intensive care (range of mean and median values, 13–20 days) settings [18]. 
We detected A(H7N9) RNA for up to 30 days in 22 patients, most of whom received a 
corticosteroid dose of at least 40 mg/day (50 mg prednisone/day), which can be considered 
an immunosuppressive dose (Supplementary Table 1). Influenza viral RNA can be detected 
in the respiratory tract, particularly the lower respiratory tract, for a prolonged period in 
patients with severe disease or immunosuppression after illness onset, and better 
understanding of the kinetics of influenza virus replication in the upper and lower 
respiratory tracts of A(H7N9)-infected patients would be useful in future studies.
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Delayed initiation of NAI treatment was an independent risk factor associated with 
prolonged A(H7N9) RNA shedding. Similarly, in a single-center retrospective study, Zheng 
et al reported that A(H7N9) RNA shedding was significantly shorter when NAI treatment 
was started within 2 days of illness onset than when antiviral treatment was started later 
[19]. The median time from illness onset to NAI treatment initiation was 8 days among the 
478 patients in our study. Earlier administration of NAI treatment might have reduced viral 
shedding and improved survival in these A(H7N9)-infected patients.
A large meta-analysis of individual-level data for patients hospitalized with A(H1N1)pdm09 
infection reported that, while early (<2 days) versus later (3–5 days) initiation of NAI 
treatment was significantly associated with a survival benefit in adults, later initiation of NAI 
treatment was significantly associated with a lower mortality risk, compared with no 
treatment [17]. Our findings also suggest that NAI treatment should be started as early as 
possible if A(H7N9) infection is suspected, without waiting for virological confirmation.
Corticosteroid therapy is commonly administrated in critically ill patients with influenza to 
reduce cytokine dysregulation and lung inflammation and to improve clinical outcomes [26]. 
However, most observational studies have reported that use of corticosteroids was associated 
with persistent viral shedding in patients with seasonal influenza, Middle East respiratory 
syndrome, or severe acute respiratory syndrome [10, 23, 27]. In addition, our previous 
observational study that used pro-pensity-score matching showed that use of high-dose 
corticosteroids was associated with a fatal outcome among patients with pneumonia and 
A(H7N9) infection [20]. Our results are in accordance with the above findings that 
corticosteroid treatment, not only high-dose corticosteroid dosing, is associated with 
prolonged viral shedding duration and that prolonged viral shedding is associated with a 
fatal outcome. The mechanisms of delayed viral clearance due to corticosteroid treatment 
are not well defined but might be associated with impaired T-cell responses [10]. Taken 
together, our findings suggest that corticosteroids should not be given for treatment of 
A(H7N9) infection.
Another potential reason for prolonged duration of viral RNA shedding is the emergence of 
NAI resistance during antiviral treatment. Hu et al [28] reported the emergence of osel-
tamivir-resistant virus with the Arg292Lys (R292K) mutation in the gene encoding viral 
neuraminidase in 2 A(H7N9)-infected patients during NAI treatment, which was temporally 
associated with a rebound in the A(H7N9) load and treatment failure. The R292K mutation 
confers resistance to oseltamivir and highly reduced inhibition to peramivir and zanamivir in 
vitro, suggesting that NAI treatment would not be effective in treating infection with viruses 
containing the R292K mutation. Of concern, the prevalence of the R292K mutation has 
increased since the first human infections with A(H7N9), in 2013, and was reported to be 
approximately 11% among sequenced viruses from A(H7N9)-infected patients during the 
fifth epidemic [4]. Recently, Ke et al [29] described the detection of the R292K mutation as 
early as 2 days after starting oseltamivir treatment in a patient with highly pathogenic 
A(H7N9) infection.
Our study is the first to assess the impact of different NAI regimens, including combination 
treatment, and different dosages of oseltamivir on viral shedding and clinical outcome in 
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patients with A(H7N9) infection. Our finding that double-dose oseltamivir did not provide 
an additional virologic benefit as compared to standard-dose oseltamivir treatment is 
consistent with results from controlled trials in outpatients [30] and inpatients with seasonal 
influenza [31] and from observational studies in hospitalized patients with A(H5N1) [32] or 
A(H1N1) pdm09 [33] infections. Previous studies suggested reasons for these observations 
[31, 34]. Oseltamivir is generally well absorbed and rapidly converted to the active 
compound, oseltamivir carboxylate, with a bioavailability of >80% [35]. Blood 
concentrations of oseltamivir carboxylate associated with single- or double-dose therapy in 
patients with influenza both exceed the median inhibitory concentration (ie, 0.7–2.2 ng/ mL 
[36]) of influenza viruses. Exceeding these concentrations might not produce additional 
clinical or virological effect [37]. In addition, it may be that delayed antiviral treatment, 
when severe disease is already present, may reduce any potential benefit of double-dose 
oseltamivir. A retrospective analysis from a limited number of patients with A(H7N9) 
infection reported that oseltamivir plus peramivir was not superior to oseltamivir 
monotherapy in clinical or virological outcomes [38]. Clinical data, including a randomized 
trial of combination oseltamivir and zanamivir treatment, compared with either monotherapy 
alone, for seasonal influenza have not substantiated a potential advantage in using 
combinations of NAIs [30]. Rather, the data appear consistent in showing that use of 
combinations that target the same protein do not show an additive or synergistic effect 
against influenza virus infection [39].
This study has several limitations. First, our study was limited by its retrospective nature, 
with dosing of antivirals missing in some patients during the first 3 epidemics. Second, not 
all of the patients with laboratory-confirmed A(H7N9) infection in mainland China could be 
included in this study. However, we were able to include patients managed at 96 different 
hospitals. Third, owing to the small number of patients who initiated NAI treatment 2–3 
days of illness onset, we were not able to assess the effect of early versus later initiation of 
NAI treatment. Fourth, genetic sequencing was not performed on specimens from patients 
with prolonged duration of A(H7N9) RNA shedding, to assess the frequency of emergence 
of antiviral resistance. It was therefore not possible to analyze the relationship between 
antiviral resistance and prolonged A(H7N9) shedding. Since paired upper and lower 
respiratory tract specimens were not collected prospectively from all patients, we could not 
directly compare differences in viral shedding between upper (ie, nasopharyngeal swab 
specimens) versus lower (endotracheal aspirates) respiratory tract specimens. However, we 
did not find any significant difference in the duration of A(H7N9) shedding between 
nasopharyngeal swab specimens and endotracheal aspirates.
In conclusion, prolonged A(H7N9) RNA shedding in the respiratory tract was independently 
associated with delayed initiation of NAI treatment and with use of corticosteroids. These 
results reinforce guidance that NAI treatment should be started as soon as possible in 
patients with suspected A(H7N9) infection and suggest that corticosteroids should be 
avoided except in clinical situations where they have proven benefit. Although a prospective, 
randomized, controlled study is needed to definitely assess the clinical and virologic benefit 
of combination NAI therapy or higher dosing of oseltamivir, our findings in this 
observational study suggest that there is no benefit of higher oseltamivir dosing or use of 
multiple NAIs for treatment of A(H7N9)-infected patients. The increased frequency of 
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emergence of resistance to NAIs during treatment and the high case-fatality proportion 
indicate an urgent need for improved antiviral treatment strategies, including drugs with 
different mechanisms of action than NAIs or those used in combination with NAIs, in 
hospitalized patients with A(H7N9) infection. Ideally, when available, new drugs should be 
evaluated in the context of randomized, controlled trials in A(H7N9)-infected patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow diagram of hospitalized patients with confirmed avian influenza A(H7N9) virus 
infection included into this study.
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Figure 2. 
Distribution of antiviral treatment (ARV) and proportion of patients with undetectable avian 
influenza A(H7N9) virus RNA by day after onset of symptom
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Figure 3. 
A, Cumulative proportion of patients between patients who survived and those who died 
with detectable avian influenza A(H7N9) virus RNA, by day after onset of illness. B, 
Cumulative proportion of patients who started neuraminidase inhibitor (NAI) therapy <5 
days versus ≥5 days after illness onset who had detectable A(H7N9) RNA, by day after 
onset of illness. C, Cumulative proportion of patients treated with oseltamivir versus 
oseltamivir and peramivir who had detectable A(H7N9) RNA, by day after onset of illness. 
D, Cumulative proportion of patients treated with oseltamivir (75 mg twice daily) versus 
oseltamivir (150 mg twice daily) with detectable A(H7N9) RNA, by day after onset of 
illness. CI, confidence interval.
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Figure 4. 
Duration of avian influenza A(H7N9) virus RNA detection in relationship to time from 
illness onset to antiviral treatment initiation.
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Table 1.
Characteristics of 478 Hospitalized Patients With Avian Influenza A(H7N9) Virus Infection in China From 1 
April 2013 to 1 March 2017
Characteristic   Value
Age, y   56 (45–66)
Male sex 340 (71.1)
Comorbidity
 Hypertension 158 (33.1)
 Diabetes    67 (14.0)
 Cardiac diseasea    44 (9.2)
 COPD    20 (4.2)
 Chronic renal insufficiency    17 (3.6)
 Immunosuppressionb   7 (1.5)
Severity score and laboratory finding on admission
 SOFA score   5 (3–6)
 White blood cell count, ×109 cells/L   4.3 (2.9–6.9)
 Lymphocyte count, ×109 lymphocytes/L   0.5 (0.3–0.7)
 Platelet count, ×109 platelets/L   130 (93–172)
 Creatinine level, μmol/L 74.0 (57.0–98.0)
 PaO2/FiO2, mm Hg   120 (76–199)
 AST level, U/L    70 (42–130)
 Creatine kinase level, U/L   290 (102–750)
Time to virological result, d
 From illness onset to A(H7N9) infection diagnosis    8 (6–10)
 From A(H7N9) infection diagnosis to ART start     1(0–1)
 From symptom onset to ART start    8 (6–10)
 Viral shedding durationc 15.5 (12–20)
Treatment or complication
 Corticosteroid therapy   346 (72.4)
 Septic shock   166 (34.7)
 ICU admission   355 (74.3)
 Invasive mechanical ventilation   249 (52.1)
 ECMO  64 (13.4)
 CRRT  89 (18.6)
Outcome
 ICU length of stay, d  13 (7–25)
 Hospital length of stay, d  18 (11–27)
 In-hospital mortality   178 (37.2)
Continuous variables are expressed as median values (interquartile ranges), and categorical variables are presented as number of patients 
(percentages). Normal ranges and definition of abnormal values for white blood cell count, lymphocytes, platelets, creatinine, PaO2/ FiO2, AST, 
and creatine kinase are listed in the Supplementary Tables and Figures.
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Abbreviations: ARV, antiviral treatment; AST, aspartate aminotransferase; COPD, chronic obstructive pulmonary disease; CRRT, continuous renal 
replacement therapy; ECMO, extra-corporeal membrane oxygenation; FiO2, fraction of inspired oxygen; ICU, intensive care unit; NAI, 
neuraminidase inhibitor; PaO2, partial pressure of oxygen; SOFA, sequential organ failure assessment.
a
Includes congestive heart disease and coronary atherosclerotic heart disease.
b
Defined as receipt of chemotherapy or radiotherapy within 1 month before the onset of illness or receipt of corticosteroid therapy (equivalent of 30 
mg of prednisone per day) for 15 continuous days before the onset of illness.
c
Data are based on real-time reverse transcription-polymerase chain reaction analysis.
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